ACC 2026 Clinical Insights: Advancing Cardiovascular Care

1-6 of 6

• 

  RestartResume

  Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis

  RestartResume

  Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis

  Cardiology

  Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis

  Javier Morales, MD, FACP, FACE

  • 

    

    Javier Morales, MD, FACP, FACE

• 

  RestartResume

  Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights

  RestartResume

  Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights

  Cardiology

  Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights

  Dr. Robert Giugliano

  • 

    

    Dr. Robert Giugliano

• 

  RestartResume

  Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV

  RestartResume

  Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV

  Cardiology

  Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV

  Nicholas Marston, MD

  • 

    

    Nicholas Marston, MD

• 

  RestartResume

  SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  RestartResume

  SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  Cardiology

  SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  Joseph Rossano, MD

  • 

    

    Joseph Rossano, MD

• 

  RestartResume

  Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors

  RestartResume

  Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors

  Cardiology

  Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors

  Florian Rader, MD

  • 

    

    Florian Rader, MD

• 

  RestartResume

  Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors

  RestartResume

  Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors

  Cardiology

  Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors

  Joseph Rossano, MD

  • 

    

    Joseph Rossano, MD